IGF1R and neoplasm: The Pediatric Preclinical Testing Program (PPTP) reported mixed results of anti-IGF-1R treatments developed for clinical use in Ewing sarcoma xenograft models; these were evaluated with larger starting tumor volumes, between 200 and 500 mm3 [31].